A time trade-off study in the UK, Canada and the US to estimate utilities associated with the treatment of haemophilia

Table 4 Utility gain/disutility associated with aspects of haemophilia treatment elicited for people living with haemophilia

	UK			Canada			US
	N	Utility	95% CI	N	Utility	95% CI	N	Utility	95% CI
Monthly vs weekly SC injections w. prefilled pen	269	0.014*	0.009;0.020	261	0.011*	0.004;0.018	229	0.010*	0.002;0.018
SC injections w. prefilled pen vs syringe once a month	234	0.031*	0.021;0.040	239	0.030*	0.020;0.040	201	0.032*	0.019;0.044
SC injections w. prefilled pen vs double dose w. syringe once a month	234	0.052*	0.040;0.066	239	0.052*	0.040;0.065	201	0.043*	0.030;0.056
Monthly SC injections w. prefilled pen vs weekly IV infusions	265	0.059*	0.049;0.070	199	0.041*	0.026;0.056	233	0.043*	0.029;0.059
Monthly SC injections w. prefilled pen vs weekly SC injections w. syringe	234	0.047*	0.036;0.059	239	0.047*	0.036;0.059	201	0.041*	0.029;0.052
Avoid injection site reactions	234	0.013*	0.005;0.021	239	0.013*	0.006;0.022	201	0.002	-0.010;0.014

ISSN: 1477-7525